Skip to content
Open access

Suboptimal outcomes of first-line chemotherapeutic regimens for advanced stages of classical Hodgkin lymphoma

Sep 2026 · Oncohematology · 0 citations · 9 references

Abstract

Background. Despite high efficacy of chemotherapy in Hodgkin lymphoma (HL), a substantial proportion of patients (about 20 %) still experience relapse or refractory disease. This study was aimed to analyze efficacy and toxicity of most widely-used chemotherapy regimens for advanced-stage HL at a single center. Materials and methods. The retrospective analysis included adult patients with advanced-stage HL (n = 107) who received treatment at the P. A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, between 2019 and 2024. Results. Of the 107 patients, 86 received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) or a BEACOPP-like regimen, and 21 received ABVD (doxorubicin, bleomycin, vinorelbine, dacarbazine). The overall response rate after completion of therapy was 93.5 %, and the complete metabolic response rate was 92.5 %. With a median follow-up of 26 (10–44) months, overall survival was 98.1 %, and progression-free survival was 78.5 %. Exploratory subgroup analysis showed a negative impact on progression-free survival of a high International Prognostic Score value (hazard ratio 1.13; 95 % confidence interval 2.60–6.02; p = 0.03), presence of extranodal lesions (hazard ratio 5.67; 95 % confidence interval 1.66–19.09; p = 0.006), and bone marrow involvement (hazard ratio 3.19; 95 % confidence interval 1.18–8.61; p = 0.02). Toxicity was comparable between treatment groups, although BEACOPP-like regimens were associated with higher hematologic toxicity. Conclusion. The most commonly used chemotherapy protocols for advanced-stage HL provide only suboptimal disease control in this setting.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.